Xellar’s Liver-on-a-Chip delivers mechanism-anchored, human-relevant DILI data — validated across 100+ compounds — so you can identify hepatotoxicity risk early, protect your clinical program, and move forward with confidence.
Hepatotoxicity is one of the most common — and most preventable — causes of clinical program failure. The models most teams rely on simply aren’t built for human liver biology.
The Xellar DILI platform co-cultures primary human hepatocytes with liver sinusoidal endothelial cells, stellate cells, and Kupffer cells on OC-PLEX 32 & OC-PLEX 96 — reconstituting the liver microenvironment to generate mechanism-anchored, pharma-grade safety data.
This isn’t a DILI assay. It’s a DILI intelligence platform — four layers working together to deliver mechanism-anchored, decision-quality safety data.
A streamlined, end-to-end workflow — you ship your compounds, we deliver actionable DILI intelligence.
“We already run hepatocyte assays — why do we need this?” Here is what you’re missing.
A fraction of the cost of a Phase I surprise. A fraction of the time of a clinical hold.
Xellar offers a complimentary DILI Risk Review for your lead compound — a 30-minute conversation with our science team to assess your current safety data and identify where our platform can reduce your clinical risk.
Leave us a request and we will contact you soon.
